Survival outcomes in patients with lenalidomide-associated ALL. (A) EFS among patients in cohort actively treated for B-ALL. (B) OS in the entire cohort. EFS (C) and OS (D) from time of transplant in subgroup of patients undergoing allogenic HCT.